PIAE risk minimized by additional treatment

Article

Treatment of blepharitis before injection, avoidance of subconjunctival anaesthesia and topical antibiotic administration immediately after injection all contribute to minimizing the risk of contracting post-intravitreal anti-VEGF endophthalmitis (PIAE).

Treatment of blepharitis before injection, avoidance of subconjunctival anaesthesia and topical antibiotic administration immediately after injection all contribute to minimizing the risk of contracting post-intravitreal anti-VEGF endophthalmitis (PIAE), claims a study in Eye.

Dr D. A. Lyall et al., Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK, conducted a prospective observational case control study on 47 patients with PIAE.

Patients were identified through the British Ophthalmological Surveillance Unit from January 2009 to March 2010 and data was gathered at diagnosis and at six months follow-up. The measures included patient demographics, intravitreal injection details, pre- and post-injection management, visual acuity, clinical features and management of PIAE, causative organisms and clinical outcomes. All subjects were compared to 200 control participants from 10 control centres to determine potential risk factors.

Positive microbiology culture was discovered in 59.6% of patients and the majority of causative organisms were Gram positive. The significant risk factors included failure to administer topical antibiotics immediately after the injection, blepharitis, subconjunctival anaesthesia, patient squeezing during the injection and failure to administer topical antibiotics before anti-VEGF injection.

The abstract can be viewed here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.